Company Quick10K Filing
Aradigm
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 15 $18
S-1 2018-11-30 Public Filing
10-Q 2018-11-15 Quarter: 2018-09-30
10-Q 2018-08-14 Quarter: 2018-06-30
10-Q 2018-05-15 Quarter: 2018-03-31
10-K 2018-03-23 Annual: 2017-12-31
10-Q 2017-11-03 Quarter: 2017-09-30
10-Q 2017-08-11 Quarter: 2017-06-30
10-Q 2017-05-15 Quarter: 2017-03-31
10-K 2017-03-30 Annual: 2016-12-31
10-Q 2016-11-10 Quarter: 2016-09-30
10-Q 2016-08-11 Quarter: 2016-06-30
10-Q 2016-05-10 Quarter: 2016-03-31
10-K 2016-03-30 Annual: 2015-12-31
10-Q 2015-11-12 Quarter: 2015-09-30
10-Q 2015-08-13 Quarter: 2015-06-30
10-Q 2015-05-11 Quarter: 2015-03-31
10-K 2015-03-18 Annual: 2014-12-31
10-Q 2014-11-07 Quarter: 2014-09-30
10-Q 2014-08-11 Quarter: 2014-06-30
10-Q 2014-05-14 Quarter: 2014-03-31
10-K 2014-03-13 Annual: 2013-12-31
10-Q 2013-10-28 Quarter: 2013-09-30
10-Q 2013-08-09 Quarter: 2013-06-30
10-Q 2013-05-14 Quarter: 2013-03-31
10-K 2013-03-27 Annual: 2012-12-31
10-Q 2012-11-08 Quarter: 2012-09-30
10-Q 2012-08-10 Quarter: 2012-06-30
10-Q 2012-05-11 Quarter: 2012-03-31
10-K 2012-03-28 Annual: 2011-12-31
10-Q 2011-11-10 Quarter: 2011-09-30
10-Q 2011-08-09 Quarter: 2011-06-30
10-Q 2011-05-13 Quarter: 2011-03-31
10-K 2011-03-25 Annual: 2010-12-31
10-Q 2010-11-12 Quarter: 2010-09-30
10-Q 2010-08-13 Quarter: 2010-06-30
10-Q 2010-05-14 Quarter: 2010-03-31
10-K 2010-03-24 Annual: 2009-12-31
8-K 2019-10-30 Other Events, Exhibits
8-K 2019-10-15 Other Events, Exhibits
8-K 2019-06-06 Enter Agreement
8-K 2019-04-23 Other Events
8-K 2019-02-15 Other Events, Exhibits
8-K 2019-02-13 Bankruptcy, Off-BS Arrangement, Officers, Exhibits
8-K 2019-01-23 Officers
8-K 2019-01-11
8-K 2019-01-04
8-K 2019-01-02 Enter Agreement, Off-BS Arrangement, Officers, Exhibits
8-K 2018-11-15 Earnings, Exhibits
8-K 2018-11-01 Off-BS Arrangement, Exhibits
8-K 2018-10-26 Officers, Exhibits
8-K 2018-10-25 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2018-09-12 Off-BS Arrangement, Exhibits
8-K 2018-09-05
8-K 2018-08-14 Earnings, Exhibits
8-K 2018-08-13 Off-BS Arrangement, Exhibits
8-K 2018-07-13 Off-BS Arrangement, Exhibits
8-K 2018-06-29 Shareholder Rights, Officers, Shareholder Vote, Other Events, Exhibits
8-K 2018-06-13 Off-BS Arrangement, Exhibits
8-K 2018-05-31 Officers, Other Events, Exhibits
8-K 2018-05-14 Off-BS Arrangement, Exhibits
8-K 2018-05-14 Earnings, Exhibits
8-K 2018-05-01 Off-BS Arrangement, Exhibits
8-K 2018-04-18 Enter Agreement, Exhibits
8-K 2018-04-13 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2018-03-23 Earnings, Exhibits
8-K 2018-03-06 Officers, Other Events
8-K 2018-02-28 Officers
8-K 2018-02-26 Officers
8-K 2018-02-09 Officers
8-K 2018-01-29 Other Events, Exhibits

Aradigm Financials

ARDM Metrics, Comps, Filings

Annual | Quarterly

Business

Aradigm Corporation (the "Company," "our company," "we," "our," or "us") are an emerging specialty pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Over the last decade, we invested a large amount of capital to develop drug delivery technologies, particularly the development of a significant amount of expertise in respiratory (pulmonary) drug delivery as incorporated in our lead product candidate that recently completed two Phase 3 clinical trials, Linhaliq inhaled ciprofloxacin, formerly known as Pulmaquin®. The key asset we have focused our efforts on in recent years is our inhaled ciprofloxacin formulations.

We believe that our cash and cash equivalents of approximately $7.1 million as of December 31, 2017, will only be sufficient to fund our operations for the first quarter of 2018. We will not be able to maintain our current level of regulatory and product development activity and there is substantial doubt about our company's ability to continue as a going concern unless we raise additional capital in early 2018. Accordingly, we need to raise additional capital through the issuance of debt or equity securities, royalty financing transactions, strategic transactions or otherwise to enable us to maintain our business operations and to continue development of our lead product candidate Linhaliq and other products, and if we are unable to do so we will need to dispose of our assets or technology or cease operations. The discussion of future prospects of our business below is based on the assumption that we are able to obtain the necessary capital to continue to operate our business as described below.

On February 9, 2018, our Board of Directors approved temporary measures intended to preserve our cash resources until additional sources of capital can be identified. These cash preservation measures include, among other things, the termination of the Amended and Restated Aradigm Corporation Executive Officer Severance Benefit Plan, the reduction of the annual base salary of certain executive officers to 50% of their then current annual base salaries, and the reduction of cash compensation paid to members of the Board for services on the Board or committees of the Board to 50% of the then current cash compensation.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Silver Bull Resources (SVBL) 18,906 -4.0 -40% 10,243 590 0 0 -4,085 -4,079 16,471
Alpha-En (ALPE) 18,741 -3.5 -235% 2,219 1,719 0 0 -5,209 -5,082 17,943
Medite Cancer Diagnostics (MDIT) 18,662 24% -9.8 -29% 17,651 11,213 8,133 1,928 -5,123 -2,912 28,437
ChineseInvestors.com (CIIX) 18,649 21% -1.7 -230% 4,424 7,640 7,189 1,541 -10,191 -10,013 17,337
Bionik Laboratories (BNKL) 18,329 1.4 44% 30,231 4,656 0 1,822 13,438 13,583 19,253
Bullfrog Gold (BFGC) 17,984 -17.4 -150% 720 613 0 0 -1,077 -1,012 17,557
Security Devices International (SDEV) 17,707 31% -5.9 -105% 2,782 2,868 170 53 -2,916 -2,886 16,968
Aradigm (ARDM) 17,655 0% -5.4 -340% 3,758 27,220 4,380 0 -12,780 -8,487 45,703
AuraSource (ARAO) 17,496 85% -13.4 -3,809% 34 4,026 35 30 -1,306 -1,306 17,462
New Jersey Mining (NJMC) 17,302 0% -18.3 -14% 11,048 2,210 4,731 17 -1,493 -931 17,041
Seafarer Exploration (SFRX) 17,265 -25.3 -274% 251 356 0 -282 -687 -683 17,263
Sun Biopharma (SNBP) 17,166 -8.1 -297% 1,339 1,456 0 0 -3,979 -2,026 16,445
Fulcrum Therapeutics (FULC) 17,076 2.6 -20% 65,151 11,696 0 0 -13,169 -13,169 -33,644
Defense Technologies (DTII) 17,057 -19.8 -825% 104 3,160 0 0 -859 -859 17,041
Norris (NRIS) 16,994 0% -17.9 -38% 2,638 2,261 492 0 -1,012 -940 16,853
Greystone Logistics (GLGI) 16,825 12% 5.4 5% 42,986 40,301 71,077 8,240 2,057 7,027 38,268
Texas Mineral Resources (TMRC) 16,807 -22.5 -194% 383 2,177 0 0 -745 -745 16,788
Park Place Energy (PKPL) 16,725 0% -6.7 -28% 8,427 6,259 3,297 0 -2,382 -2,382 15,989
Viking Energy (VKIN) 16,416 0% -7.2 -15% 134,210 123,592 21,568 0 -20,249 -10,736 77,493
iShares Commodity Optimized Trust (CMDT) 16,407 0% 17.8 -89,334,900% 201 0 893 893 15,858

Balance Sheet ($'000)2011-06-302011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Cash8,4812,1487,41448,13147,99031,46222,5917,095
Accounts Receivable
Inventory
PP&E1,3191,11372712,183502299253289
Assets11,91510,5568,96650,42453,96335,62625,0548,065
Accounts Payable2121963306192,7061,789711903
Long-Term Debt
Liabilities11,7539,86710,40716,74114,84812,51624,06720,596
Stockholders' Equity162689-1,44133,68339,11523,110987-12,531
Income Statement ($'000)2011-06-302011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Revenue9,71733,56123,42919514,465
Cost of Revenue
Gross Profit
R&D5,0073,7818,88431,17235,27624,38713,815
SG&A4,2743,8964,7756,2265,2945,8287,592
Tax000000
Net Income-9,309-8,226-21,5644,652-17,209-32,938-10,705
Cash Flow ($'000)2011-06-302011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Cash Operating-9,770-6,651264107-16,703-28,480-16,498
Cash Investing-6,3396,293131-412-1,081852
Cash Financing12,9625,62440,32216417520,690150